Table 3 Post-recurrence survival of patients with stage I NSCLC in previous studies

Current study

LUAD: 1028

LUSC: 276

LASC: 49

Others: 34

LUAD:210

LUSC: 65

LASC: 19

Others: 7

301 (21.7%)

Locoregional recurrence: 71 (23.6%); Distant metastasis: 230 (76.4%)

75.1% (1-year)

55.1%(2-year)

37.2%(3-year)

16.6%(5-year)

architectural grade (micropapillary and solid predominant); recurrence site of brain or bone

Ujiie et al. [5]

LUAD: 1120

LUAD: 188

188 (17%)

Locoregional recurrence: 59 (31%) Distant metastasis: 129 (69%)

67% (1-year)

45% (2-year)

36% (3-year)

14% (5-year)

Older age (>65 yr) at the time of recurrence; sublobar resection; solid predominant; distant metastasis;

Shimada et al. [6]

LUAD: 919

LUAD: 46

Non-LUAD: 46

170 (18%)

Locoregional recurrence: 43 (25%) distant metastasis: 113 (66%) locoregional recurrence + distant metastasis: 14 (9%)

73% (1-year)

51% (2-year)

PRT; male sex; poorly differentiated

Hung et al. [16]

LUAD: 283

LUAD: 283

57 (20%)

72.3% (2-year)

31.6% (5-year)

Micropapillary and solid predominant

Song et al. [20]

NSCLC

LUAD: 46

LUSC: 15

Other: 11

72 (15%)

Locoregional recurrence: 36 (50%) distant metastasis: 36 (50%)

88% (1-year)

53% (3-year)

Bad response for treatment; Recurrence-free interval<12 months

Hung et al. [7]

NSCLC

LUAD: 95

LUSC: 46

Other: 25

Distant metastasis: 166 (17.8%)

Single organ metastasis: 106

Multiple organ metastasis: 60

37.7% (1-year)

18.9% (2-year)

Disease-free interval more than 16 months

Hung et al. [19]

NSCLC

LUAD: 45

LUSC: 60

Other: 18

Locoregional recurrence: 123 (13.2%)

Local only: 74 locoregional recurrence + distant metastasis: 49

48.0% (1-year)

18.7% (2-year)

PRT (chemotherapy, surgery, and/or radiotherapy)

Nakagawa et al. [18]

LUAD:300

LUSC: 89

Other: 8

87

87 (21.9%)

Locoregional recurrence: 30 (34.5%)

Distant metastasis: 57 (65.6%)

67.7% (1-year)

34.4% (3-year)

Symptoms at recurrence: liver or cervico-mediastinum; PRT (non-surgery/surgery)